Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-OPS202 for Imaging GEP-NETs
NCT02162446Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jun 2014
- Primary completion
- Jun 2015
- Modality
- Alpha Emitters, Beta Emitters, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of satoreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Ipsen. Started Jun 2014; status: completed.
02
Drugs
satoreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT02162446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162446.